▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Dave Williamson

XMFGreenwave4

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Recent Articles by Dave Williamson

Feb 4, 2014 by Dave Williamson

Why Gilead Sciences, Inc. Won Big Today

Gilead Sciences won big in the biotech space today. How should investors play this move?

Feb 4, 2014 by Dave Williamson

Why Furiex Pharmaceuticals Inc. Is an Instant Double

Furiex pulls the classic biotech instant double. How should investors play this fast-moving stock?

Jan 31, 2014 by Dave Williamson

Why Vanda Pharmaceuticals Won Big Today

How an FDA approval for this sleep/wake disorder drug made Vanda Pharmaceuticals today's big biotech winner.

Jan 31, 2014 by Dave Williamson

Why InterMune Inc. Lost Big Today

Here's why InterMune was hit hard today, through no fault of its own.

Jan 30, 2014 by Dave Williamson

Why Alexion Pharmaceuticals and Dicerna Pharmaceuticals Inc Won Big Today

Two massive winners in biotech stocks today, including one staggeringly skyrocketing IPO.

Jan 28, 2014 by Dave Williamson

Investors Focus on Fortune-Making Immuno-Oncology Race

Who will win the high-stakes immuno-oncology race?

Jan 28, 2014 by Dave Williamson

How Gilead Sciences, Inc. Could Push Back on Sovaldi Pricing

The price for Gilead's new hepatitis C cure seems exorbitant to some, and now pharmacy benefit managers are starting to push back along with the protestors. Here's why Gilead's pricing will still probably hold.

Jan 28, 2014 by Dave Williamson

Decoding Pfizer Inc.'s Strong Earnings and Game-Changing Pipeline

Here's why Pfizer is absolutely a stock to watch in the months ahead.

Jan 28, 2014 by Dave Williamson